SenesTech Reports 2% Revenue Growth to $493,000 in Q1 2026

SenesTech, Inc. reported a net revenue of $493,000 for the first quarter of 2026, reflecting a 2% increase from $485,000 in the same period of 2025. The growth was primarily driven by sales of the Evolve product line, which includes Evolve Rat and Evolve Mouse, accounting for approximately 85% of total revenue. In contrast, sales of the ContraPest product line experienced a decline, contributing to the overall revenue increase being less pronounced than in previous quarters. The company reported a gross profit of $338,000, yielding a gross margin of 68.6%, up from 64.5% in the prior year, attributed to improved production efficiency and pricing strategies.

Operating expenses for the quarter rose to $2.5 million, a 24% increase compared to $1.98 million in the first quarter of 2025. This increase was largely due to higher selling, general, and administrative expenses, which climbed 31% to $2.04 million, driven by legal fees related to litigation settlements and increased marketing costs. Research and development expenses remained relatively stable at $422,000, reflecting a slight increase from $418,000 in the previous year. The company reported a net loss of $2.06 million for the quarter, compared to a loss of $1.67 million in the same period last year.

In terms of operational metrics, SenesTech's total assets decreased to $11.06 million as of March 31, 2026, down from $12.84 million at the end of 2025. The company's cash and cash equivalents also fell to $6.8 million, compared to $7.58 million at the end of the previous fiscal year. The decline in cash reserves was attributed to ongoing operational losses, although the company noted an increase in interest income due to a higher average balance of cash and investments. The total liabilities increased slightly to $3.36 million, with current liabilities accounting for $938,000.

Strategically, SenesTech has focused on expanding its distribution channels, particularly in e-commerce and retail, to enhance the market presence of its Evolve product line. The company has also been working on optimizing its manufacturing processes to improve cost efficiency. Looking ahead, SenesTech anticipates that its current cash reserves, combined with expected revenue, will be sufficient to fund operations into the third quarter of 2027. However, the company acknowledges the potential need for additional financing to support ongoing commercialization efforts and operational expenses, particularly if revenue growth does not meet expectations.